Rectiv (nitroglycerin) / Kyowa Kirin, Endo - LARVOL DELTA

Cosette Pharmaceuticals Announces the Approval and Launch of First Generic Version of RECTIV (nitroglycerin) ointment, 0.4%, with 180 days Competitive Generic Therapy (CGT) exclusivity (Businesswire) - "Cosette Pharmaceuticals, Inc...announced that the U.S. Food and Drug Administration (FDA) has approved the Abbreviated New Drug Applications (ANDA) for the first generic version of RECTIV (nitroglycerin) ointment, 0.4%, with 180 days Competitive Generic Therapy (CGT) exclusivity. Cosette will imminently commence commercial shipments, triggering the 180 days exclusivity...This launch will enable Cosette to continue to build upon its unparalleled quality track record and leverage its United States based manufacturing site in Lincolnton, NC....According to IQVIA™, U.S. annual sales of nitroglycerin ointment 0.4% for the 12 months ended January 2024 were approximately $21.2 million."

ANDA • Generic launch • Sales • CNS Disorders • Pain

"EVERYTHING Rectiv would be useful" (@drjerber)

Aptalis Pharma announces agreement to market Rectiv in the U.S (Marketwire) - Aptalis Pharma announced that it has signed an exclusive license agreement with ProStrakan Group plc to market Rectiv (nitroglycerin) ointment 0.4% in the U.S. for the treatment of moderate to severe pain associated with chronic anal fissure

Licensing agreement • Pain

"@Allergan don’t you think charging $700 for medication is immoral, excessive and just downright extortionist in nature? #rectiv #medication #bigpharma #extortion" (@alluneediz1mik3)